The Journal of Practical Medicine >
STAT activation inhibitory protein 2 is involved in reprogramming of lipid metabolism by regulating the prostate cancer development
Received date: 2025-06-05
Online published: 2025-09-25
Objective To investigate the expression level of the protein inhibitor of the activated STAT2 （PIAS2） gene in prostate cancer and its relationship with clinicopathological features， and the potential role of PIAS2 in reprogramming lipid metabolism in prostate cancer. Methods The Cancer Genome Atlas Program （TCGA） database and HPA immunohistochemical analysis were used to show the expression of PIAS2 protein； qRT-PCR， Western bolt and immunohistochemistry were used to detect PIAS2 in prostate cancer tissues and their paracancerous tissues. PIAS2 expression in prostate cancer tissues and its paracancerous tissues and analyzed its relationship with clinicopathological features of patients； lentivirus infected prostate cancer cell line PC-3M， which stably knocked down PIAS2， was analyzed by ultra performance liquid chromatography mass spectrometry （UPLC-MS） for lipidomics. Results TCGA analysis showed that the expression of PIAS2 in prostate cancer tissues was higher than that in paracancerous tissues， and HPA immunohistochemistry analysis showed that PIAS2 protein was highly expressed in prostate cancer tissues； the expression of PIAS2 mRNA and protein was significantly elevated in prostate cancer compared with that in paracancerous tissues， and the difference was statistically significant （P < 0.05）； immunohistochemistry showed that PIAS2 protein Expression of PIAS2 protein was mainly localized in the nucleus of prostate， and the AOD value of prostate cancer tissues was significantly higher than that of paraneoplastic tissues： the results of clinicopathological parameters showed that PIAS2 had correlation with Gleason score and TNM stage （P < 0.05）， while there was no statistically significant correlation with the age of the patients， PSA and lymph node metastasis； UPLC-MS analysis suggested that the knockdown of PIAS2 affected 10 lipid changes， with down-regulation of phosphatidylcholine and phosphatidylethanolamine and up-regulation of phosphatidylinositol， phosphatidylserine， diacylglycerol， and triacylglycerol in the shPIAS2 group compared with the shNC group. Conclusions The expression of PIAS2 protein was significantly elevated in prostate cancer tissues， suggesting that PIAS2 is associated with the development of prostate cancer， and its pathogenesis may be related to the abnormal lipid metabolism of prostate cancer.
Weizun LI , Chen XING , Hengqing AN . STAT activation inhibitory protein 2 is involved in reprogramming of lipid metabolism by regulating the prostate cancer development[J]. The Journal of Practical Medicine, 2025 , 41(18) : 2844 -2852 . DOI: 10.3969/j.issn.1006-5725.2025.18.009
| [1] | CAO W， CHEN H D， YU Y W， et al. Changing profiles of cancer burden worldwide and in China： A secondary analysis of the global cancer statistics 2020［J］. Chin Med J （Engl）， 2021， 134（7）： 783-791. doi:10.1097/cm9.0000000000001474 |
| [2] | LI X， RASUL A， SHARIF F， et al. PIAS family in cancer： From basic mechanisms to clinical applications［J］. Front Oncol， 2024， 14： 1376633. doi:10.3389/fonc.2024.1376633 |
| [3] | GHAFOURI-FARD S， HUSSEN B M， NICKNAFS F， et al. Expression Analysis of Protein Inhibitor of Activated STAT in Inflammatory Demyelinating Polyradiculoneuropathy［J］. Front Immunol， 2021， 12：659038. doi:10.3389/fimmu.2021.659038 |
| [4] | MAGALHAES J， TRESSE E， EJLERSKOV P， et al. PIAS2-mediated blockade of IFN-β signaling： A basis for sporadic Parkinson disease dementia［J］.Mol Psychiatry， 2021， 26（10）： 6083-6099. doi:10.1038/s41380-021-01207-w |
| [5] | LI C， BOUTET A， PASCARIU C M， et al. SUMO Proteomics Analyses Identify Protein Inhibitor of Activated STAT-Mediated Regulatory Networks Involved in Cell Cycle and Cell Proliferation［J］. J Proteome Res， 2023， 22（3）： 812-825. doi:10.1021/acs.jproteome.2c00557 |
| [6] | KUKKULA A， OJALA V K， MENDEZ L M， et al. Therapeutic Potential of Targeting the SUMO Pathway in Cancer［J］. Cancers （Basel）， 2021， 13（17）：4402. doi:10.3390/cancers13174402 |
| [7] | RODRIGUES J S， CHENLO M， BRAVO S B， et al. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe［J］. Nat Commun， 2024， 15（1）： 3736. doi:10.1038/s41467-024-50135-0 |
| [8] | LIANG J， LI L， LI L， et al. Lipid metabolism reprogramming in head and neck cancer［J］. Front Oncol， 2023， 13： 1271505. doi:10.3389/fonc.2023.1271505 |
| [9] | TANG M， LI X， REN J， et al. Limosilactobacillus reuteri HM108 alleviates obesity in rats fed a high-fat diet by modulating the gut microbiota， metabolites， and inhibiting the JAK-STAT signalling pathway［J］. Front Nutr， 2025， 12：1597334. doi:10.3389/fnut.2025.1597334 |
| [10] | KONG X， CHEN H， LI D， et al. Effects of imbalance of lipid metabolism through NF-κB pathway on atherosclerosis and vascular aging in rats［J］. Cell Mol Biol （Noisy-le-grand）， 2022， 67（5）： 144-150. doi:10.14715/cmb/2021.67.5.20 |
| [11] | 杨剑波，邵继春，曾治军，等. lncRNA MIF-AS1调节miR-423-5p/PYCR1轴对前列腺癌细胞恶性生物学行为的影响［J］. 实用医学杂志， 2024， 40（18）： 2544-2549. |
| [12] | SHU H， CHEN X， ZHAO J， et al. PIAS family gene expression： Implications for prognosis， immunomodulation， and chemotherapy response［J］. Am J Transl Res， 2024， 16（11）： 6346-6364. doi:10.62347/jrdp4018 |
| [13] | PENG Y， LEE J， ZHU C， et al. A novel role for protein inhibitor of activated STAT （PIAS） proteins in modulating the activity of Zimp7， a novel PIAS-like protein， in androgen receptor-mediated transcription［J］. J Biol Chem， 2010， 285（15）： 11465-11475. doi:10.1074/jbc.m109.079327 |
| [14] | 杨锐，易成，陈钢鑫，等. PIAS2蛋白和生精细胞凋亡在无精子症中相关性的研究［J］. 中国优生与遗传杂志， 2022， 30（7）： 1177-1181. |
| [15] | DU J， DU Y， CHEN L， et al. IL-17 promotes melanoma through TRAF2 as a scaffold protein recruiting PIAS2 and ELAVL1 to induce EPHA5［J］. Biochim Biophys Acta Mol Cell Res， 2023， 1870（7）： 119547. doi:10.1016/j.bbamcr.2023.119547 |
| [16] | LI Y， LIN H， SHU S， et al. Integrative transcriptome analysis reveals TEKT2 and PIAS2 involvement in diabetic nephropathy［J］. FASEB J，2022，36（11）：e22592. doi:10.1096/fj.202200740rr |
| [17] | WADA H， SUZUKI D， NIIKURA T. Regulation of ALS-Associated SOD1 Mutant SUMOylation and Aggregation by SENP and PIAS Family Proteins［J］. J Mol Neurosci，2020，70（12）：2007-2014. doi:10.1007/s12031-020-01604-w |
| [18] | GHAFOURI-FARD S， HESAMI O， NAZER N， et al. Expression of PIAS Genes in Migraine Patients［J］. J Mol Neurosci， 2021， 71（10）： 2053-2059. doi:10.1007/s12031-021-01834-6 |
| [19] | LIU Y， LIAO S， BENNETT S， et al. STAT3 and its targeting inhibitors in osteosarcoma［J］.Cell Prolif， 2021， 54（2）： e12974. doi:10.1111/cpr.12974 |
| [20] | MOHAN C D， RANGAPPA S， NAYAK S C， et al. Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma［J］. Biochim Biophys Acta Rev Cancer， 2021， 1876（1）： 188574. doi:10.1016/j.bbcan.2021.188574 |
| [21] | WU R， FANG J， LIU M， et al. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1， UBC9， and PIAS2 and enhances its stability and function in cell proliferation［J］.J Biol Chem，2020， 295（19）：6741-6753. doi:10.1074/jbc.ra119.012338 |
| [22] | CHEN S Y， CHIANG C F， SU Y F， et al. Protein inhibitor of activated signal transducer and activator of transcription 2 is an oncoprotein in oral squamous cell carcinoma and related to cigarette smoking - An in vitro study［J］. J Dent Sci， 2024， 19（4）： 1983-1990. doi:10.1016/j.jds.2024.07.013 |
| [23] | PENNEY K L， TYEKUCHEVA S， ROSENTHAL J， et al. Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum［J］.Mol Cancer Res， 2021， 19（3）： 475-484. doi:10.1158/1541-7786.mcr-20-0548 |
| [24] | 徐焕铭. CRNDE调控PIAS2介导急性髓细胞白血病预后调节机制的研究［D］. 沈阳： 中国医科大学， 2021. |
| [25] | 贾雯茜. STAT3介导苏氨酸调控HepG2细胞甘油三酯沉积［D］. 扬州： 扬州大学， 2024. |
| [26] | YANG M， WU S， CAI W， et al. Hypoxia-induced MIF induces dysregulation of lipid metabolism in Hep2 laryngocarcinoma through the IL-6/JAK-STAT pathway［J］.Lipids Health Dis， 2022，21（1）： 82. doi:10.1186/s12944-022-01693-z |
| [27] | STOICA C， FERREIRA A K， HANNAN K， et al. Bilayer forming phospholipids as targets for cancer therapy［J］. Int J Mol Sci， 2022， 23（9）： 5266. doi:10.3390/ijms23095266 |
| [28] | LIU Q， ZHANG X， QI J， et al. Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC［J］. Hepatology， 2025， 81（4）： 1164-1180. doi:10.1097/hep.0000000000000962 |
| [29] | LI X， NAKAYAMA K， GOTO T， et al. High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer［J］. Cancer Sci， 2021， 112（10）： 4292-4302. doi:10.1111/cas.15093 |
| [30] | GUAN Y， CHEN X， WU M， et al. The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy［J］. J Hepatol， 2020， 72（4）： 746-760. doi:10.1016/j.jhep.2019.11.007 |
/
| 〈 |
|
〉 |